Join Now

Yearly Archives: 2022

Data Results Published in American Journal of Managed Care demonstrate adoption and clinical utility of KidneyIntelXTM with Primary Care Physicians

By Natalie Themm | Published August 8, 2022

98% of 401 Primary Care Physicians confirmed KidneyIntelX has value as a risk decision tool in their adult patients with type 2 diabetes and chronic kidney disease stages 1-3b.

Posted in BioUtah News | Tagged | Leave a comment

Soft Cell Labs announces new Urinary Tract Infection Test

By Natalie Themm | Published August 8, 2022

Soft Cell Labs announces new Urinary Tract Infection Test

Posted in BioUtah News | Tagged | Leave a comment

ELITechGroup and InfanDx AG to Collaborate on the Development and Manufacturing of HypoxE® Neonatal Care Test for Clinical Laboratories

By Natalie Themm | Published August 4, 2022

ELITechGroup to provide contract development and manufacturing services for HypoxE® IVD Tests designed for Selectra Pro family of clinical chemistry analyzers

Posted in BioUtah News | Tagged , | Leave a comment

bioMérieux receives FDA Clearance for NEPHROCHECK® test on VIDAS®

By Natalie Themm | Published August 4, 2022

bioMérieux receives FDA Clearance for NEPHROCHECK® test on VIDAS®

Posted in BioUtah News | Tagged | Leave a comment

3M Announces Plans to Create Long Term Value Through Spin-Off of Health Care Business

By Natalie Themm | Published August 4, 2022

New 3M will remain a leading global material science innovator serving diverse end markets, with science and technology, manufacturing, global capabilities, and iconic brands

Posted in BioUtah News | Tagged | Leave a comment

Tillis and Leahy Introduce Bipartisan Legislation to Improve Patent Quality

By Natalie Themm | Published August 3, 2022

Tillis and Leahy Introduce Bipartisan Legislation to Improve Patent Quality

Posted in BioUtah News, Policy News | Leave a comment

Senate Democrats Push Drug Pricing, Tax, Climate Package

By Denise Bell | Published July 28, 2022

Sen. Joe Manchin (D-W. Va.) on Wednesday said he had signed off on a revised “Build Back Better” plan, renamed the “Inflation Reduction Act of 2022,” which includes sweeping drug price controls along with tax increases and billions for climate and energy spending. The bill’s drug pricing provisions would allow Medicare to negotiate drug prices […]

Posted in Policy News | Leave a comment

UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2022

By Natalie Themm | Published July 28, 2022

UTMD achieved second calendar quarter (2Q) and first half (1H) 2022 financial results better than those anticipated in its beginning of year projections.

Posted in BioUtah News | Tagged | Leave a comment

Sumitomo Pharma Oncology Receives Orphan Drug Designation for DSP-0390, an Investigational Emopamil-binding Protein (EBP) Inhibitor for the Treatment of Brain Cancer

By Natalie Themm | Published July 28, 2022

Sumitomo Pharma Oncology recently announced the U.S. FDA granted Orphan Drug Designation for DSP-0390, an investigational emopamil-binding protein (EBP) inhibitor for the treatment of brain cancer. 

Posted in BioUtah News | Tagged | Leave a comment

Forbes Magazine Recognizes ARUP Among Nation’s Best Employers for Women

By Natalie Themm | Published July 28, 2022

ARUP Laboratories’ ongoing commitment to provide an environment of diversity, inclusion, and belonging for all employees has earned the company recognition as one of Forbes magazine’s Best Employers for Women 2022. The Forbes ranking, first published online on Tuesday, July 26, places ARUP 236th on a list of 300 companies nationwide. Winners were chosen based […]

Posted in BioUtah News | Tagged | Leave a comment

Published UCLA and Spectrum Saliva Liquid Biopsy Research Highlights Signal Amplifying Ability and Clear Detection of Cancer Biomarkers

By Natalie Themm | Published July 28, 2022

Spectrum Solutions announced the publishing of findings from their research collaboration with the University of California at Los Angeles (UCLA) and Dr. David Wong, UCLA School of Dentistry.

Posted in BioUtah News | Tagged | Leave a comment

Clene’s ALS Drug Increases Survival by 70% in Mid-stage Study

By Natalie Themm | Published July 28, 2022

Shares of Clene, Inc. surged Thursday after the company released “golden” data from an interim analysis of a Phase II study.

Posted in BioUtah News | Tagged | Leave a comment

A Special Thanks To Our Legacy and Platinum Elite Members